oral trivalent reassortant rotavirus live attenuated vaccine

Oral trivalent reassortant rotavirus live attenuated vaccine is a **live-attenuated, orally administered, trivalent rotavirus vaccine** developed by Lanzhou Institute of Biological Products. It contains genetically reassorted rotavirus vaccine viruses produced in Vero cells and is intended to prevent infant rotavirus gastroenteritis and associated diarrhea. The product was evaluated in the Phase 3 trial NCT01738074 under the intervention name \"trivalent rotavirus genetic reassortment vaccine\" and was subsequently approved in China as an oral trivalent reassortant rotavirus live attenuated vaccine. Public reports describe protection against diarrhea associated with rotavirus G1, G2, G3, G4, and G9 types. This product is distinct from RotaShield, a withdrawn tetravalent rhesus-human reassortant rotavirus vaccine. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01738074))

Brand names

RotaShield

Other names

trivalent rotavirus genetic reassortment vaccineoral trivalent reassortant rotavirus live attenuated vaccine Vero cells口服三价重配轮状病毒减毒活疫苗